NanoViricides, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsNanoViricides is a clinical-stage biopharmaceutical company developing nanoviricide drugs to treat viral diseases, with no approved products or revenue.
What they do
NanoViricides develops nanoviricide drugs using a platform that mimics host receptors to bind and dismantle viruses. Its lead candidate, NV-387, has completed Phase Ia/Ib safety trials and is Phase II-ready for COVID-19. The company has no customers, products, or revenue and relies on funding to advance its pipeline.
Revenue drivers
- No approved products — The company has no revenue from any product; all revenue is $0.00 for fiscal years 2021-2025.
Recent performance
For the fiscal year ended June 30, 2025, NanoViricides reported a net loss of $9.5 million, up from $8.3 million in 2024. Diluted EPS improved to -$0.63 from -$0.70. Operating cash flow was -$8.5 million in 2025. As of March 31, 2026, the company had cash and equivalents of $3.2 million and total shareholders' equity of $9.2 million.
Strategy
NanoViricides is advancing NV-387, its broad-spectrum antiviral, toward Phase II efficacy trials, with a clinical study report nearing completion for submission in India. The company is also developing other candidates, including NV-HHV-1, in late-stage IND-enabling studies. Management emphasizes the platform's potential to avoid virus escape and its safety profile as key advantages.
Risks
- No revenue or products — The company has no customers, products, or revenue and may never achieve profitability.
- Clinical and regulatory uncertainty — NV-387 has only completed Phase Ia/Ib safety trials; Phase II efficacy and regulatory approvals are not assured.
- Funding risk — With only $3.2 million in cash, the company may need additional capital to continue operations and clinical trials.
- Early-stage pipeline — Most drug candidates are in pre-clinical development and may fail to advance or receive regulatory approval.
Outlook
Management anticipates submitting the final clinical study report for NV-387 to the regulatory agency in India soon, which is a step toward Phase II trials. The company continues to invest in its nanoviricide platform and additional pre-clinical candidates. However, significant work remains before any product can be commercialized.